Clevidipine hair loss is best approached with timeline logic, because most medication-linked shedding behaves like telogen effluvium (TE): the trigger happens first, and increased shedding becomes noticeable later. For clevidipine, a dihydropyridine calcium channel blocker (CCB), the current evidence is more nuanced than a simple “yes” or “no.” Current Cleviprex (clevidipine) injectable emulsion labeling does not clearly list alopecia as a named common adverse effect. Instead, the label is centered on acute blood-pressure control when oral therapy is not feasible or not desirable, with common adverse reactions such as headache, nausea, and vomiting. That means suspected shedding around clevidipine is usually best interpreted through timing + pattern + competing acute-care triggers, rather than through a strong direct alopecia label signal.
Medical note: This article is for general education and does not provide personal medical advice. Do not stop or change clevidipine or any blood-pressure treatment without clinician guidance. If you are not sure whether you are seeing shedding or breakage, start here: Shedding vs Breakage. If the diagnosis is unclear, start here: How Hair Loss Is Diagnosed. If you have scalp pain/burning, pustules/crusting, heavy scale, open sores, or rapid worsening, start here: When to See a Doctor.
Quick navigation
- Key takeaways
- What the product information says / what it doesn’t
- Timeline: onset, peak, recovery
- Pattern clues: TE vs AGA vs AA vs breakage
- Why causation is tricky in acute-care settings
- When labs matter
- What to do
- When to see a doctor
- FAQ
- References
Key takeaways
- The current clevidipine label does not clearly show a strong alopecia signal: alopecia is not clearly listed as a named common adverse effect in current labeling.
- The drug context is different from many other CCB pages: clevidipine is an IV injectable emulsion used when oral therapy is not feasible or not desirable, usually in an acute-care setting rather than as a long-term outpatient pill.
- The common adverse-reaction picture is different: the most common adverse reactions listed at >2% are headache, nausea, and vomiting.
- Warnings matter: the label highlights hypotension and reflex tachycardia, and it also warns about rebound hypertension if a prolonged infusion is stopped without transition to other therapy.
- TE timing still matters: if shedding is related to the drug or the surrounding illness/procedure context, it is often noticed about 2–4 months after a trigger and may become obvious around 3 months after a trigger.
- Pattern matters: TE is usually diffuse and non-scarring, not a single smooth bald patch.
- Acute-care overlap is the big clue: many patients receiving clevidipine also have severe hypertension, perioperative care, or hospitalization-level stressors that can themselves fit TE logic.
- Related on this site: Calcium Channel Blocker Hair Loss: Risk & Timeline • Nimodipine Hair Loss: Risk, Timeline & Fixes • Isradipine Hair Loss: Risk, Timeline & Fixes • Medication-Related Shedding • Hair Loss After Surgery: TE vs Pressure Alopecia • Telogen Effluvium.
What the product information says / what it doesn’t
What the current label does say: current Cleviprex (clevidipine) injectable emulsion labeling describes a dihydropyridine calcium channel blocker indicated for reduction of blood pressure when oral therapy is not feasible or not desirable. It is an intravenous drug, not a routine oral outpatient medicine.
Why that matters for hair-loss interpretation: a short IV antihypertensive used during severe hypertension, perioperative care, or another acute medical setting creates a different diagnostic situation from a long-term daily tablet. When shedding shows up later, the practical question is often whether the trigger was the drug itself, the acute illness/procedure, or a stacked overlap.
What the label highlights most: the common adverse reactions listed at >2% are headache, nausea, and vomiting. The label also warns that hypotension and reflex tachycardia can happen with rapid upward titration.
Important context from the trials: in perioperative studies, the label notes that many adverse events were associated with the operative procedure itself, which limits how cleanly the drug’s own adverse-event profile can be separated from the surrounding clinical context.
What it does not clearly show: in the current labeling reviewed for this article, alopecia is not clearly listed as a named common adverse effect or strong molecule-level hair-loss signal.
Other safety details that matter clinically: clevidipine is contraindicated in patients with allergy to soy or eggs, defective lipid metabolism, or severe aortic stenosis. The product also contains lipid, which matters in some hospitalized patients.
Timeline: onset, peak, recovery
For most practical suspected post-hospital or medication-shedding cases, the most useful model is telogen effluvium.
- Onset: the key clue is delay. Hair fall is often noticed about 2–4 months after a trigger and can occur around 3 months after a trigger.
- Peak: once shedding starts, it may feel worst for several weeks.
- Recovery: once the trigger is addressed or stabilizes, shedding usually slows first; visible density recovery takes longer.
- Duration clue: acute TE shedding often lasts about 3–6 months, but cosmetic regrowth usually takes longer.
This delay is why the story is often misread. A patient may receive clevidipine during an acute event, leave the hospital, and only much later notice more hair in the shower, on the pillow, or on the brush. That delayed pattern fits hair-cycle timing much better than a dramatic same-day infusion explanation.
Pattern clues: TE vs AGA vs AA vs breakage
Most consistent with TE
Medication- or illness-linked TE usually looks like diffuse shedding with a generally normal-looking scalp. You notice more hair fall all over, not one sharply defined bald patch.
TE + androgenetic alopecia overlap
If shedding improves but the part line keeps widening or the crown continues to thin, think about overlap with telogen effluvium vs androgenetic alopecia.
Alopecia areata is a different pattern
If you have patchy, smooth, well-defined bald areas, that is less typical for TE and should raise the question of alopecia areata.
Breakage is not the same as shedding
If you mostly see short snapped hairs, rough texture, or frayed ends, that points more toward hair breakage than true root-level shedding.
If there are allergy-type or inflammatory clues, think broader than TE
Quiet delayed TE is different from a patient who has rash, hives, facial swelling, or a visibly inflamed scalp. In those settings, a broader medication-reaction or non-TE explanation becomes more important.
Why causation is tricky in acute-care settings
This is the part that makes clevidipine hair loss different from many routine blood-pressure pages. The exposure often happens during an acute medical event, not a quiet outpatient medication start.
That means several plausible TE triggers may stack together in the same window:
- major surgery or perioperative stress
- severe illness
- hospital-level physiologic stress
- rapid medication changes
- reduced intake or weight change during recovery
- iron or thyroid overlap if shedding persists or the history suggests it
So if shedding starts later, the right question is often not “Was I on clevidipine?” alone. The more useful question is whether the overall timeline fits TE from the acute event + treatment context.
When labs matter
Not every patient with a plausible post-hospital TE story needs a broad lab panel. But labs matter more when shedding is heavy, persistent, recurrent, or the history suggests overlap causes such as iron deficiency, thyroid disease, marked weight change, low intake, or another systemic stressor.
For the site workup roadmap, use: Blood Tests & Workup.
What to do (practical plan)
- Build the timeline carefully: write down the reason clevidipine was used, the hospital/procedure dates, any major illness dates, and the month shedding became noticeable.
- Confirm the pattern: diffuse shedding vs breakage vs overlap pattern hair loss vs patchy loss.
- Review stacked triggers: surgery, severe illness, major stress, reduced intake, weight change, and other new medications in the same 2–4 month window.
- Look for non-TE clues: rash, hives, facial swelling, or a very inflamed scalp suggest a different pathway than quiet delayed TE.
- Do not assume one-cause certainty: in acute-care settings, shedding may be multifactorial.
- Talk to the treating team: if the diagnosis is unclear, review the entire recovery timeline instead of focusing on one drug name alone.
- Track monthly: use photos every 4 weeks in the same lighting and angle so you can judge trend, not day-to-day anxiety.
When to see a doctor
- Scalp pain, burning, pustules, open sores, or heavy scale/crusting
- Patchy smooth bald spots rather than diffuse shedding
- Obvious eyebrow or eyelash involvement
- Facial swelling, hives, or another possible drug-reaction pattern
- Shedding that persists beyond about 6 months or returns in repeated waves
- Rapid worsening or unclear diagnosis
Start here: When to See a Doctor.
FAQ
Does the current clevidipine label clearly list alopecia?
No. In the current labeling reviewed for this page, alopecia is not clearly listed as a named common adverse effect.
What are the most common adverse reactions in the label?
The current label lists headache, nausea, and vomiting as the most common adverse reactions at >2%.
Why is causation harder to judge with clevidipine?
Because clevidipine is often used during severe hypertension, perioperative care, or other acute medical settings where surgery, illness, and other stressors can also fit TE timing.
Is clevidipine hair loss permanent?
When the pattern behaves like telogen effluvium, it is usually non-scarring and reversible once the trigger or recovery stress stabilizes, but regrowth takes time.
Should I blame clevidipine if hair shedding starts months later?
Not automatically. The safer approach is timeline-based: review the procedure/illness context, recovery stress, nutrition, and medication changes together rather than assuming one single cause.
References (trusted sources)
- DailyMed PDF: Cleviprex (clevidipine) injectable emulsion — indication, adverse reactions, warnings, contraindications, and acute-care trial context
- DailyMed label page: Cleviprex (clevidipine) emulsion
- DermNet: Alopecia from drugs
- DermNet: Telogen effluvium
- British Association of Dermatologists: Telogen effluvium
- NCBI Bookshelf (StatPearls): Telogen Effluvium
Last updated: March 14, 2026.
